Sinopharm: The revenue in the first half of the year was 3.585 billion yuan, an increase of 15.1% year-on-year.

Announcement from SenseTime Pharmaceutical: As of June 30, 2025, for the six months ended, the Group's revenue amounted to RMB 35.85 billion, an increase of 15.1% compared to RMB 31.14 billion in the same period in 2024. The profit attributable to equity shareholders of the Company was RMB 6.04 billion, an increase of RMB 1.47 billion compared to RMB 4.57 billion in the same period in 2024, representing a growth of 32.2%. Adjusted profit attributable to equity shareholders of the Company was RMB 6.51 billion, an increase of RMB 1.13 billion compared to RMB 5.38 billion in the same period in 2024, representing a growth of 21.1%.